The effect of SGLT2 inhibitor on glomrular hyperfiltration in type 2 diabetes patients.

Not Applicable

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000026887
• Lead Sponsor: Abe Diabetes Clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-04-09
• Study Completion: 2019-01-26
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

1. The amount of change of eGFR between screening and initiation of study is more than 10ml/min/1.73m2 2. Patient with type 1 diabetes mellitus or with history of secondary diabetes mellitus 3. Patients with history of or concurrent complication that affect renal function(renal disease, nephrotic syndrome and so on)or patients with dialysis 4. Patients with the history of serious hepatic diseases. 5. Patients with history of myocardial infarction, congestive heart failure, unstable angina, cerebrovascular disease within 6 months prior to screening visit (confirmation of eligibility) 6. Patients with history of or concurrent complication that affect digestive function 7. Patients with the history of serious diabetic complications requiring treatment 8. Patients with history of malignant tumor 9. Patients with a history of drug allergies that interfere with participation in the clinical trial. 10. Patients suspected of alcohol or drug abuse. 11. Pregnant women, nursing mothers, or patients who do not agree to contraception during study period. 12. Patients with diabetes receiving SGLT2 inhibitor in the 8 weeks prior to screening period. 13. Patients who are judged as inappropriate by investigators on screening examination.

Study & Design

• Study Type: Interventional
• Study Design: Not specified